| Premier Eyecare, Angela Tsai, O.d. And Associates, P.c. | |
|
230 Butler Road, Fredericksburg, VA 22405 | |
| (540) 373-3021 | |
| (540) 373-5565 |
| Full Name | Premier Eyecare, Angela Tsai, O.d. And Associates, P.c. |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 230 Butler Road, Fredericksburg, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134137086 | NPI | - | NPPES |
| 061203 | Other | VA | ANTHEM BCBS |
| 410011188 | Other | VA | RAILROAD MEDICARE |
| 410011189 | Other | VA | RAILROAD MEDICARE |
| 9203915 | Medicaid | VA | |
| 010302005 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 0618000130 (Virginia) | Primary |
| 152W00000X | Optometrist | 0618000447 (Virginia) | Secondary |
| Provider Name | Bradley W Church |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1790762821 PECOS PAC ID: 5294762894 Enrollment ID: I20050726000455 |
News Archive
Findings from a national study by researchers at Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and external collaborators suggest that sex and age are crucial factors in the care and survival of patients with malignant brain tumors and other central nervous systems (CNS) cancers.
USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.
The tumor suppressor CYLD lysine 63 deubiquitinase (CYLD) is a deubiquitinating enzyme that suppresses polyubiquitin-dependent signaling pathways, including the proinflammatory and cell growth-promoting NF-κB pathway.
The risk and fear of falling often affects patients who are recovering from a stroke, spinal cord or brain injury, and orthopaedic injuries, and that fear may inhibit their progress in rehabilitation.
› Verified 5 days ago
| Provider Name | Angela Tsai |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1598781148 PECOS PAC ID: 4981604386 Enrollment ID: I20070109000462 |
News Archive
Findings from a national study by researchers at Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and external collaborators suggest that sex and age are crucial factors in the care and survival of patients with malignant brain tumors and other central nervous systems (CNS) cancers.
USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.
The tumor suppressor CYLD lysine 63 deubiquitinase (CYLD) is a deubiquitinating enzyme that suppresses polyubiquitin-dependent signaling pathways, including the proinflammatory and cell growth-promoting NF-κB pathway.
The risk and fear of falling often affects patients who are recovering from a stroke, spinal cord or brain injury, and orthopaedic injuries, and that fear may inhibit their progress in rehabilitation.
› Verified 5 days ago
| Provider Name | Samuel Smart |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1023196276 PECOS PAC ID: 2264534254 Enrollment ID: I20100308000781 |
News Archive
Findings from a national study by researchers at Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and external collaborators suggest that sex and age are crucial factors in the care and survival of patients with malignant brain tumors and other central nervous systems (CNS) cancers.
USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.
The tumor suppressor CYLD lysine 63 deubiquitinase (CYLD) is a deubiquitinating enzyme that suppresses polyubiquitin-dependent signaling pathways, including the proinflammatory and cell growth-promoting NF-κB pathway.
The risk and fear of falling often affects patients who are recovering from a stroke, spinal cord or brain injury, and orthopaedic injuries, and that fear may inhibit their progress in rehabilitation.
› Verified 5 days ago
| Provider Name | Lauren Schwalb |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1629521570 PECOS PAC ID: 8224397534 Enrollment ID: I20180112000955 |
News Archive
Findings from a national study by researchers at Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and external collaborators suggest that sex and age are crucial factors in the care and survival of patients with malignant brain tumors and other central nervous systems (CNS) cancers.
USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.
The tumor suppressor CYLD lysine 63 deubiquitinase (CYLD) is a deubiquitinating enzyme that suppresses polyubiquitin-dependent signaling pathways, including the proinflammatory and cell growth-promoting NF-κB pathway.
The risk and fear of falling often affects patients who are recovering from a stroke, spinal cord or brain injury, and orthopaedic injuries, and that fear may inhibit their progress in rehabilitation.
› Verified 5 days ago
| Provider Name | Lauren Rabon |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1992226336 PECOS PAC ID: 0446521900 Enrollment ID: I20201028000763 |
News Archive
Findings from a national study by researchers at Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and external collaborators suggest that sex and age are crucial factors in the care and survival of patients with malignant brain tumors and other central nervous systems (CNS) cancers.
USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.
The tumor suppressor CYLD lysine 63 deubiquitinase (CYLD) is a deubiquitinating enzyme that suppresses polyubiquitin-dependent signaling pathways, including the proinflammatory and cell growth-promoting NF-κB pathway.
The risk and fear of falling often affects patients who are recovering from a stroke, spinal cord or brain injury, and orthopaedic injuries, and that fear may inhibit their progress in rehabilitation.
› Verified 5 days ago
| Provider Name | Stephanie Lambertson |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1104558972 PECOS PAC ID: 8820473879 Enrollment ID: I20220912003916 |
News Archive
Findings from a national study by researchers at Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and external collaborators suggest that sex and age are crucial factors in the care and survival of patients with malignant brain tumors and other central nervous systems (CNS) cancers.
USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.
The tumor suppressor CYLD lysine 63 deubiquitinase (CYLD) is a deubiquitinating enzyme that suppresses polyubiquitin-dependent signaling pathways, including the proinflammatory and cell growth-promoting NF-κB pathway.
The risk and fear of falling often affects patients who are recovering from a stroke, spinal cord or brain injury, and orthopaedic injuries, and that fear may inhibit their progress in rehabilitation.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Premier Eyecare, Angela Tsai, O.d. And Associates, P.c. 230 Butler Road, Fredericksburg, VA 22405 Ph: (540) 373-3021 | Premier Eyecare, Angela Tsai, O.d. And Associates, P.c. 230 Butler Road, Fredericksburg, VA 22405 Ph: (540) 373-3021 |
News Archive
Findings from a national study by researchers at Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and external collaborators suggest that sex and age are crucial factors in the care and survival of patients with malignant brain tumors and other central nervous systems (CNS) cancers.
USHIFU LLC, a world leader in minimally invasive high intensity focused ultrasound technologies and manufacturer of the Sonablate 500 (Sonablate) medical device, announces results from the first-ever prospective clinical investigation of HIFU with the Sonablate to focally treat prostate cancer, a modality in which only the confirmed cancerous regions within the gland are treated as opposed to the entire prostate. Results from the study appear in this month's Journal of Urology.
The tumor suppressor CYLD lysine 63 deubiquitinase (CYLD) is a deubiquitinating enzyme that suppresses polyubiquitin-dependent signaling pathways, including the proinflammatory and cell growth-promoting NF-κB pathway.
The risk and fear of falling often affects patients who are recovering from a stroke, spinal cord or brain injury, and orthopaedic injuries, and that fear may inhibit their progress in rehabilitation.
› Verified 5 days ago
Dr. Carissa Lee Novotny, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 625 Warrenton Rd Ste 105, Fredericksburg, VA 22406 Phone: 540-374-1445 | |
National Vision Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 9829 Patriot Hwy, Fredericksburg, VA 22407 Phone: 540-376-6888 | |
Dr. Sarah Pilat Brannon, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 12100 Kennedy Ln, Ste 206, Fredericksburg, VA 22407 Phone: 540-785-3937 Fax: 540-785-5498 | |
Samuel C Smart, DOCTOR OF OPTOMETRY Optometrist Medicare: Medicare Enrolled Practice Location: 230 Butler Road, Fredericksburg, VA 22405 Phone: 540-373-3021 Fax: 540-373-5565 | |
Eye Doctor Office, Inc. Optometrist Medicare: Medicare Enrolled Practice Location: 3102 Plank Rd Ste 395, Fredericksburg, VA 22407 Phone: 540-786-2020 | |
Steffani A. Deas, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 110 Cambridge Street, Access Eye Centers, Fredericksburg, VA 22405 Phone: 540-371-2020 Fax: 540-373-0141 | |
Dr. Cambrie Shae Chandler, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 12 Chatham Heights Rd Ste 100, Fredericksburg, VA 22405 Phone: 800-572-2722 |